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Three Decades of Experience in Managing Immune
Thrombocytopenia in Children in Arab Countries
Mohsen Saleh ElalfyThere are scattered and limited data in the literature on immune thrombocytopenia (ITP) in0037-1963
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S22children from the Arab region. The aim of the current review is to present data from this region
on the diagnosis, therapy, and morbidity associated with ITP. The first report was published
three decades ago. It was assumed that there was a different disease pattern of ITP, but this was
later discovered to be inaccurate and the frequencies of different ITP patterns were not
different from other regions. The initial work-up for diagnosis of newly diagnosed ITP included
routine bone marrow evaluation for all patients in most studies; however, a limited need for
bone marrow for the initial evaluation was reported. An Egyptian multicenter study on the
morbidity and mortality of intracranial hemorrhage (ICH) with other sporadic data was
reported. Neither regional nor national guidelines for ITP management in most Arab countries
have been reported. However, the use of initial intravenous immunoglobulin (IVIG) therapy in
the Arabian Gulf region in contrast to corticosteroids in most other countries was obvious.
Limited data on the use of anti-CD20, avoidance of unnecessary splenectomy, and the use of
thrombopoietin receptor analogue in chronic ITP were published recently. A unified consensus
for ITP management in the Arab region is essential but not yet realistic. More publications from
this region are needed.
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hree-hundred sixty million people live in the
Arab world: one third in Asia and two thirds
in Africa. Genetic blood disorders are quite
prevalent in this region because of the high rate of
consanguinity. Regarding the acquired disorders as
of immune thrombocytopenia (ITP), there are scat-
tered data in the literature over the last decades from
this region and most of the published studies are
retrospective. Some national centers have joined the
International Cooperative ITP Study Group (ICIS)
registry on an individual basis.EPIDEMIOLOGY
ITP is a heterogeneous disorder with a diverse
natural history and diverse pattern of treatment
response.1 Previously known as idiopathic thrompo-
cytopenic purpura and immune thrombocytopenicblished by Elsevier Inc.
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penia.’’2 The first report on ITP in the Arab world was
a retrospective study in 1981; they suggested that ITP
patterns in Arabs could be different from the rest of
the world, with more than 45% chronicity of ITP in
four Arab countries.3 A more recent retrospective
report from Lebanon indicated a much lower chron-
icity rate of 10% (patients not achieving remission by
6 months).4 Khalifa et al reported in a large Egyptian
study a 30% rate of chronic ITP, matching the
international reports.5 This result has been confirmed
by a more recent study.6
There was no gender preference in most acute
ITP studies; however, chronic ITP was more fre-
quent in females in Egypt.6 In contrast, reports from
the Arabian Gulf region7,8 and Lebanon4 have shown
that nearly 80% of patients with chronic ITP
were males.
A history of preceding viral infection was common
in both acute and chronic ITP cases (71% and 63%,
respectively).7 A study from Emirates on 97 patients
with ITP reported a history of upper respiratory tract
infection 10–15 days prior to development of ITP in
most of the studied cases.8 A Lebanese prospective
study showed that one third of their 50 patients
had received immunization 2–8 weeks prior to the
development of ITP.4 A mass measles/mumps/rubellaology, Vol 50, No 1, Suppl 1, January 2013, pp S22–S25
ITP in children in the Arab region S23(MMR) vaccination for Egyptian secondary school
adolescents after an epidemic of German measles in
2007 was followed by an increased incidence of ITP
in the following few weeks.9CLINICAL MANIFESTATIONS
The most common presentation of ITP was
ecchymosis and petichae in 80%–100% of cases.
However, absence of purpura does not exclude
subclinical disease.2 Hematemesis is a rare manifes-
tation, being present in none of the subjects in the
Emirate’s report8 and in 2% in the Egyptian study.6
Similarly, hematuria was reported in two Lebanese
children (4%).4 It could be a warning sign for an
associated intracranial hemorrhage (ICH).10 Epistaxis
is a common problem in pediatric ITP; it was
reported in 10% of these patients in the Kuwaiti
series.11
Ten cases of ICH were identified among children
with ITP over a period of 10 years in five Egyptian
centers: four patients had acute ITP, two persistent
ITP, and four chronic ITP.10
Patients with secondary ITP are less likely to
bleed than those with primary ITP and might have
higher platelet count at diagnosis. This could be
associated with evidence of a different or combina-
tion of autoimmune diseases.12
Splenomegaly is not a common feature of primary
ITP; however, a Kuwaiti group reported a high
prevalence of splenomegaly in 31 (55%) of 56 Arab
children with ITP. They attributed this finding to the
higher prevalence of sickle cell disease in their
patients.11
The mortality rate of ITP is very low in Arab
countries, matching the international standards of
less than 1%. Death was due to ICH in one case in
the Emirates study,8 two children in the Egyptian
study,10 and in one patient in a report from
Tunisia.13WORK-UP
Most of the Arab reports over the last three
decades have emphasized that initial laboratory
evaluation for a child with typical acute ITP should
include a complete blood cell count with a good
peripheral blood film evaluation by an expert. It is
unnecessary to request viral serology or autoimmune
work-up, especially with no clinical evidence of a
collagen vascular disease in children younger than
10 years of age. However, exclusion of secondary
ITP is essential in adolescents with ITP.10
Almost all Arab children with ITP had undergone
bone marrow examination to exclude malignancy or
marrow aplasia.7,11 The author of this report sug-
gests that it was overdone and it is unnecessary forthe initial evaluation of a typical newly diagnosed
ITP presentation in children.10 Therapy refractori-
ness or poor response to first-line ITP therapy should
warrant a review of the diagnosis and a bone marrow
examination.14,15MANAGEMENT
The management of ITP in children is not uniform
in the Arab world. It ranges from observation,
medical treatment depending on bleeding symp-
toms, acceptable platelet counts, and availability of
hospitalization or outpatient treatment.10,16
Admission to hospital is a common practice in
Arab countries, particularly in patients with platelet
countso20  109/L regardless of bleeding symp-
toms.6–8,11,12 However, less than 10% of children
with acute ITP are admitted in Egypt nowadays.6
Definitions of complete response (CR), partial
response (PR), and no response (NR) vary dramati-
cally in among studies from the Arab
region.6,8,11,12,16 We suggest to follow a uniform
and clear definition of the response to therapy based
on the recently published American Society of
Hematology (ASH) guidelines.17
In the Arab region most children with ITP with
platelet countso20  109/L initially received some
form of platelet-enhancing treatment. In the Arabian
Gulf countries the initial management consists
mainly of intravenous immunoglobulin (IVIG) given
at a dose of 1 g/kg/d for 2 consecutive days.7,8,12 A
cheaper alternative is RhoGAM (anti-D immunoglo-
bulin [Bio Products Laboratory, UK]) at 50–75 mg/kg
in a single dose. However, this treatment is less
widely used.18
In the rest of the Arab countries, these patients
are initially treated with some form of corticosteroid
therapy either intravenous methyl prednisolone
10 mg/kg/d for 2 days9 or 30 mg/kg/d for 3 days,
or conventional prednisone 2 mg/kg/d for 2–4
weeks.10 The author attributes this difference in
practice, to the difference in the national income,
which is higher in the Arabian Gulf countries and
to the absence of national and regional guidelines.
In Egypt many centers follow the international
guidelines.10
There are no published studies on management of
chronic ITP in children in the Arab world except an
interesting prospective Omani study. The authors
reported long-term remission in almost 50% of 13
refractory chronic ITP patients after 6 monthly
courses of pulsed oral dexamesathone 40 mg/m2
for 4 consecutive days.16
The management of primary ITP in adults has
changed with the advent of anti-CD20 (Rituximab
[Mabthera, Roche, Switzerland]) and thrombopoietin
receptor agonists.19,20 According to the ASH
M.S. ElalfyS24guideline, Rituximab is considered as second-line
therapy in patients who do not respond to cortico-
steroids and have repeated bleeding. A recent report
from Oman described the successful treatment with
Rituximab of an adult female with coexistence of ITP
and idiopathic membranous glomerulonephritis.21 In
unpublished data, CR was reported in 25%, PR in
25%, and NR in 50% of 12 chronic refractory
Egyptian children with ITP who received four
courses of anti-CD20 (Rituximab) 375 mg/m2
intravenously.
Splenectomy continues to induce the highest
remission rate of chronic refractory ITP. (60%–70%
at 5þ years).19 There are few publications on its use
in the Arab world. Four Kuwaiti patients were
treated by splenectomy, and it was successful in
three cases (75%).11 In a retrospective study in Iraq,
40% of chronic ITP adults had splenectomy with an
almost 80% remission rate.22 During the period
1980–1998, 112 Egyptian patients with chronic ITP
were splenectomized; at 5 years, 44 (45%) remained
in CR and 34 (35%) in PR.23
Thrombopoietin receptor agonist was reported in
only two publications from Egypt. A case series
study revealed a variable response rate in children
with chronic ITP treated with this category of
drugs.24 Ten of 12 patients (83.3%) on Romiplostim
(Amgen, CA) treatment maintained the efficacy
defined as an endpoint of platelet count450 
109/L. Romiplostim was well tolerated and efficient
in treating the children with chronic refractory ITP
with no reported unexpected adverse events.25CONCLUSION
Most of the studies and published reports on ITP
from the Arab world are retrospective and there are
few multicenter studies, even within the same
country. Collaborative groups between centers man-
aging children with ITP in this region are lacking and
their creation should be encouraged. Moreover,
standardization of practical guidelines for manage-
ment of ITP in the region is needed.Acknowledgments
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